AbCellera Biologics Inc. (ABCL) Appoints Chief Medical Officer

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best healthcare penny stocks to buy now. On September 10, the company confirmed the appointment of Sarah Noonberg, M.D., Ph.D., as its Chief Medical Officer.

She joins the company with over 20 years of industry experience, having led various development programs from discovery through regulatory approvals and commercialization. A board-certified physician-scientist, Dr. Noonberg is an excellent addition to the company, given her experience in different therapeutic areas, including oncology, neuroscience, rare diseases, gene therapy, and cell therapy.

“With more than 20 years of experience in clinical development, Sarah brings deep expertise and proven operational and leadership strength that will be invaluable as we continue to build and advance our clinical pipeline,” said Carl Hansen, Ph.D., founder and CEO of AbCellera.

AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotechnology company that uses a proprietary technology platform to discover and develop antibody-based medicines for various diseases, including cancer, autoimmune disorders, and infectious diseases. It partners with other drug developers to identify the most effective antibodies, leveraging its integrated technology, data science, and interdisciplinary teams to accelerate the drug development process.

While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best AI Stocks to Buy Under $5 and 12 Best Beginner Stocks to Buy According to Analysts.

Disclosure: None. This article is originally published at Insider Monkey.